Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

FDA extends mitapivat sickle cell review; approval decision now due February 2027.

What the company is saying

Agios Pharmaceuticals announces that the FDA has extended the PDUFA goal date for its mitapivat sNDA in sickle cell disease to February 1, 2027, following a request for additional information regarding a potential REMS. The company emphasizes that the sNDA was submitted under the accelerated approval pathway and granted Priority Review, highlighting the unmet need in sickle cell disease, which affects about 100,000 people in the U.S. CEO Brian Goff frames mitapivat as the company's largest indication and a potential significant growth driver, stating Agios is 'launch-ready' with established relationships in the hematology community. The narrative stresses the comprehensive safety data submitted—nine months of updated results from the RISE UP Phase 2 and 3 trials—and asserts that the benefit-risk profile for mitapivat in sickle cell disease remains unchanged. Agios also references ongoing confirmatory trials (REIGNITE Phase 3) and reiterates its commitment to working closely with the FDA. The announcement is confident, process-focused, and positions the regulatory delay as a standard step rather than a setback.

What the data suggests

The FDA's extension of the PDUFA goal date to February 1, 2027, is a direct result of a major amendment classification after Agios submitted additional safety data on October 19, 2026. The RISE UP Phase 3 trial randomized 207 patients (138 to mitapivat, 69 to placebo) and nearly all who completed the double-blind period entered the open-label extension, indicating strong patient retention. No cases of hepatocellular injury with a pattern or severity matching thalassemia trials have been observed in sickle cell disease patients treated with mitapivat, but this is a qualitative statement without explicit numerical safety data for this population. In thalassemia, 0.66% (2 of 301) experienced adverse reactions suggestive of hepatocellular injury in the double-blind period, with three more in the open-label extension; two required hospitalization. The sickle cell disease market is large (100,000 U.S. patients), but there is no disclosed financial data, revenue projections, or guidance. The company claims commercial readiness but provides no quantifiable evidence of launch preparedness or market access. The evidence supports regulatory progress and safety monitoring but does not substantiate commercial or financial claims.

Analysis

The announcement is a factual regulatory update regarding the FDA's extension of the PDUFA goal date for mitapivat in sickle cell disease, with detailed disclosure of process steps, trial data, and safety outcomes. The tone is measured, with most claims focused on realised regulatory milestones and clinical trial progress. Forward-looking statements, such as expectations for mitapivat as a growth driver and ongoing labeling discussions, are present but not overstated or promotional. There is no evidence of exaggerated language or narrative inflation; the company's statements about commercial readiness and market size are standard for this stage of drug development. No large capital outlay or immediate financial impact is disclosed, and the timeline for potential approval is long-term (February 2027). The gap between narrative and evidence is minimal, as the company avoids making premature claims about approval or commercial success.

Risk flags

• ●Regulatory risk remains high: the FDA's request for additional information and subsequent three-month extension indicate unresolved concerns about safety monitoring, specifically regarding the need for a REMS. This could lead to further delays or restrictive labeling.
• ●Safety risk is not fully quantified for sickle cell disease: while Agios asserts no hepatocellular injury cases similar to those in thalassemia, no explicit numerical safety data for the sickle cell population is disclosed. The thalassemia data show a 0.66% rate of adverse liver events, including serious cases requiring hospitalization.
• ●Commercialization risk persists: Agios claims to be 'launch-ready' and expects mitapivat to be a significant growth driver, but provides no details on commercial infrastructure, payer access, or market strategy. The absence of financial projections or launch timelines limits visibility on revenue impact.
• ●Execution risk tied to confirmatory trials: the REIGNITE Phase 3 trial, required for full approval, only began dosing in July 2026. Any delays or negative results in this trial could jeopardize conversion from accelerated to traditional approval and affect long-term market potential.

Bottom line

Agios faces a three-month regulatory delay for mitapivat in sickle cell disease, with the FDA decision now expected by February 1, 2027. The company has submitted extensive safety data and maintains there are no new safety signals in sickle cell patients, but provides only qualitative assurance rather than explicit numerical evidence for this group. The sickle cell disease market is large at 100,000 U.S. patients, but commercial and financial impacts remain speculative until approval and labeling are finalized. Investors should focus on the outcome of the FDA's REMS evaluation, the specifics of any imposed restrictions, and progress in the ongoing REIGNITE confirmatory trial. The most important takeaway is that regulatory and execution risks remain material, and tangible value creation is deferred until at least early 2027.

Announcement summary

(NASDAQ:AGIO) Agios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease to February 1, 2027. The sNDA was submitted under the FDA’s accelerated approval pathway and granted Priority Review. On October 9, 2026, the FDA requested additional information to evaluate whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary for mitapivat in sickle cell disease. Agios responded on October 19, 2026, submitting approximately nine months of updated safety data through October 9, 2026, from the ongoing open-label extension periods of the RISE UP Phase 2 and Phase 3 trials. The FDA classified Agios’ response as a major amendment on October 28, 2026, resulting in a three-month review extension. There continue to be no cases of hepatocellular injury (HCI) among patients with sickle cell disease treated with mitapivat that show a pattern and severity similar to those observed in the clinical trials for mitapivat in adults with thalassemia. The benefit-risk profile of mitapivat in sickle cell disease remains unchanged. Agios will continue labeling discussions with the FDA, including elements of a potential REMS. Brian Goff, Chief Executive Officer of Agios, stated that sickle cell disease affects approximately 100,000 people in the U.S. and is the largest indication pursued for mitapivat. The company expects mitapivat to be a significant growth driver and is launch-ready, building on its commercial infrastructure and relationships with hematologists, sickle cell centers, and patients. The mitapivat sNDA is based on data from the global, randomized, double-blind, placebo-controlled RISE UP Phase 2 and Phase 3 trials in patients aged 16 years or older with sickle cell disease. Mitapivat is currently approved in the U.S. for adult patients in two hemolytic anemias: pyruvate kinase (PK) deficiency (2022) and thalassemia (2025). In July 2026, Agios dosed the first patient in the REIGNITE Phase 3 trial (NCT07656415), the confirmatory clinical trial required under the U.S. accelerated approval pathway, designed to demonstrate the clinical benefit of mitapivat on reducing transfusion burden in patients with sickle cell disease aged 12 years or older. The RISE UP Phase 3 trial (NCT05031780) included a 52-week, double-blind, randomized, placebo-controlled period with 207 participants randomized 2:1 to receive oral mitapivat (100 mg) twice daily (n=138) or matched-placebo (n=69), followed by an open-label extension period. Of the 176 participants who completed the double-blind period, 174 entered the open-label extension. The RISE UP Phase 3 trial included two primary endpoints: hemoglobin response (≥1.0 g/dL increase from baseline in average hemoglobin from Week 24 through Week 52) and annualized rate of sickle cell pain crises, as well as five key secondary endpoints. During the double-blind period of the AQVESME (mitapivat) thalassemia trial, 2 of 301 patients (0.66%) experienced adverse reactions suggestive of hepatocellular injury. Three additional patients experienced adverse reactions suggestive of hepatocellular injury during the open-label extension periods after switching from placebo to AQVESME. Of these 5 patients, 2 had serious liver injury requiring hospitalization, including 1 patient who developed jaundice (peak bilirubin 32 mg/dL). Another patient developed jaundice (peak bilirubin 4 mg/dL) without requiring hospitalization. The most common adverse reactions among patients taking AQVESME were headache and insomnia. AQVESME is available only through a restricted program under a REMS called the AQVESME REMS because of the risk of hepatocellular injury. The most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency treated with PYRUKYND (mitapivat) were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Disagree with this article?